Niagen Bioscience (NAGE) Prepaid Assets (2011 - 2026)
Niagen Bioscience (NAGE) posted quarterly Prepaid Assets of $1.5 million for Q1 2026, down 37.08% year-over-year from $2.4 million in Q1 2025, and up 13.41% quarter-over-quarter from $1.3 million in Q4 2025.
Niagen Bioscience (NAGE) Prepaid Assets (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has reported Prepaid Assets for 14 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Prepaid Assets fell 37.08% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $1.5 million (down 37.08% YoY), while the FY2025 annual figure was $1.3 million, down 47.14% from the prior year.
- Prepaid Assets rose to $1.5 million in Q1 2026 per NAGE's latest filing, from $1.3 million in the prior quarter.
- Across five years, Prepaid Assets topped out at $4.3 million in Q3 2022 and bottomed at $1.3 million in Q4 2025.
- Historically, Prepaid Assets has averaged $2.2 million across 5 years, with a median of $2.1 million in 2025.
- Annual changes were most pronounced in 2022 — Prepaid Assets jumped 141.71% — and 2023, when it plunged 48.74%.
- Niagen Bioscience's Prepaid Assets stood at $3.0 million in 2022, then retreated by 17.43% to $2.4 million in 2023, then climbed by 1.31% to $2.5 million in 2024, then sank by 47.14% to $1.3 million in 2025, then climbed by 13.41% to $1.5 million in 2026.
- Business Quant data shows NAGE's Prepaid Assets at $1.5 million in Q1 2026, $1.3 million in Q4 2025, and $2.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Niagen Bioscience | 238.30 Mn | 171.56 Mn | 19.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.83 Mn |
| Mar 31, 2026 | 1.49 Mn |
| Dec 31, 2025 | 1.31 Mn |
| Sep 30, 2025 | 2.03 Mn |
| Jun 30, 2025 | 2.14 Mn |
| Mar 31, 2025 | 2.37 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 2.10 Mn |
| Jun 30, 2024 | 2.09 Mn |
| Mar 31, 2024 | 2.31 Mn |
| Dec 31, 2023 | 2.45 Mn |
| Sep 30, 2023 | 2.18 Mn |
| Jun 30, 2023 | 1.89 Mn |
| Mar 31, 2023 | 2.30 Mn |
| Dec 31, 2022 | 2.97 Mn |
| Sep 30, 2022 | 4.26 Mn |
| Jun 30, 2022 | 1.46 Mn |
| Mar 31, 2022 | 1.91 Mn |
| Dec 31, 2021 | 1.86 Mn |
| Sep 30, 2021 | 1.76 Mn |